Scientific References COSMOS Search: Publications Cited References List: Authors Conferences Journals Gray Literature Most Cited: Authors References Database Statistics: Top Viewed Articles

Connected As: <Anonymous> Contact:  srcosmos@aegean.gr

Article summary:

Giamarellos-Bourboulis EJ:
"Recent advances in the treatment of sepsis syndrome ",
Archives of Hellenic Medicine 20 (2) : 182-190 (Mar 2003)

Keywords	Antimicrobial agents, Cytokines, Immunomodulation, Sepsis
Abstract	Τhe modern concept of the effective management of the septic patient involves support with fluids, artificial respiration and inotropic agents and removal of the septic focus. This latter goal may be achieved by either surgical eradication of the septic focus or the effective administration of antimicrobial agents such as carbapenems or a combination of 3rd generation cephalosporins and aminoglycosides. The selection of an antimicrobial agent should be made cautiously since it could potentiate the septic process due to the release of endotoxins during lysis of the bacterial cell. β­lactams, which act through PBP­2 on the bacterial cell wall, such as cefuroxime, cefotaxime and ceftazidime, induce less release of endotoxins than carbapenems and quinolones. Other lines of causative management of sepsis involve immunomodulation. Monoclonal antibodies and soluble receptors of TNFα, inhibitors of nitric oxide synthase and polyunsaturated fatty acids have already been used. The intravenous administration of recombinant protein C has been proved the most effective immunomodulatory intervention. Its application is based on its inhibitory effect on the biosynthesis of pro­inflammatory cytokines. Better insight into the pathogenetic mechanisms of sepsis could lead to improved immunomodulatory therapy.
Full text	Full Text in PDF (338 KB)
Source link	http://www.mednet.gr/archives/2003-2/pdf/182.pdf
Included Refrences	71 References (List...)
Cited by other Articles	0 Citations (List...)

Authors:

Name	Affiliation	Home page	e-mail	Total pubs
Giamarellos-Bourboulis EJ	4th Department of Internal Medicine, University of Athens, Medical School, Athens, Greece		giamarel@ath.forthnet.gr	4

Article is cited by:

 No records found.

References included in article:

 71 records found. (Records 1-50)           page 1/2     

Order of appearence	Full citation	SRCosmos Link
1	AMERICAN COLLEGE OF CHEST PHYSICIANS: SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864--875
2	Rangel-Frausto MS, The epidemiology of bacterial sepsis. Infect Dis Clin North Am 1999, 13:299--311
3	Morrison DC, Silverstein R, Luchi M, Shnyra A, Structure-function relationships of bacterial endotoxins. Infect Dis Clin North Am 1999, 13:313--340
4	Kitchens RL, Thompson PA, Viriyakosol SO, Keefe GE, Munford RS, Plasma CD14 decreases monocyte responses to LPS by transferring cell­bound LPS to plasma lipoproteins. J Clin Invest 2001, 108:485--493
5	Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, ET AL. Toll­like receptor 4 imparts ligand­specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000, 105:497--504
6	Dumitru CD, Ceci JD, Tsatsanis C, Kontoyannis D, Stamatakis K, Lin JH, ET AL. TNFα induction by LPS is regulated posttranscriptionally via TpI2/ERK­dependent pathway. Cell 2000, 103:1071--1083
7	Van-Der-poll T, Van-Deventer SJH, Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999, 13:413--426
8	Sewnath ME, Olszyna DP, Birjmohun R, Ten-Kate FJW, Gouma DJ, Van-Der-poll T, IL­10­deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 2001, 166:6323--6326
9	Annane D, Sanquer V, Faye A, Djuranovic D, Raphael JC, Galdos P, ET AL. Compartmentalised inducible nitric­oxide synthase activity in septic shock. Lancet 2000, 355:1143--1148
10	Levy R, Dana R, Levy I, Weber G, Smoliakov R, Pesach I, ET AL. Elevated cytosolic phospholipase A 2 expression and activity in human neutrophils during sepsis. Blood 2000, 95:660--665
11	Winterbourn CC, Buss H, Chan TP, Plank LD, Clark MA, Windsor JA, Protein carbonyl measurements show evidence of early oxidative stress in critically ill patients. Crit Care Med 2000, 28:143--149
12	Ten-Cate H, Schoenmakers SHHF, Franco R, Timmerman JJ, Groot AP, Spek C, ET AL. Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care Med 2001, 29 (Suppl):S95--S98
13	Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, ET AL. Tumor necrosis factor­α and interleukin­1β synergistically depress human myocardial function. Crit Care Med 1999, 27:1309--1318
14	Dellinger RP, Current therapy for sepsis. Infect Dis Clin North Am 1999, 13:495--509
15	Vincent JL, Preiser JC, Management of the critically ill patient with severe sepsis. J Chemother 1999, 11:524--529
16	Sznajder JI, Alveolar edema must be cleared for the acute respiratory distress syndrome patient to survive. Am J Respir Crit Care Med 2001, 163:1293--1294
17	Brower RG, Ware LB, Berhiaume Y, Matthay MA, Treatment of ARDS. Chest 2001, 120:1347--1367
18	Eisner MD, Thompson T, Hudson LD, Luce JM, Hayden D, Schoenfeld D, ET AL. Efficacy of low tidal volume ventilation in patients with different risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001, 164:231--236
19	Astiz ME, Rackow EC, Septic shock. Lancet 1998, 351:1501--1505
20	Wheeler AP, Berbard GR, Treating patients with severe sepsis. N Engl J Med 1999, 340:207--214
21	Hyatt JM, Mc-Kinnon PS, Zimmer GS, Schentag JJ, The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995, 28:143--160
22	Craig WA, Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad­spectrum cephalosporins. Diagn Microbiol Infect Dis 1995, 22:89--96
23	MADARAS­KELLY K J, OSTERGAARD B E, HOVDE L B, ROTSCHAFER J C. Twenty­four­hour area under the concentration­time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996, 40:627--632
24	Bochud PY, Glauser MP, Calandra T, Antibiotics in sepsis. Intensive Care Med 2001, 27(Suppl 1):S33--S48
25	Wood MJ, Chemotherapy for Gram­positive nosocomial sepsis. J Chemother 1999, 11:446--452
26	Periti P, Mazzei T, Antibiotic­induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review. J Chemother 1998, 10:427--448
27	Jackson JJ, Kropp H, Beta­lactam antibiotic­induced release of free endotoxin: in vitro comparison of penicillin­binding protein (PBP)­2 specific imipenem and PBP­3 specific ceftazidime. J Infect Dis 1992, 165:1033--1041
28	Frieling JMT, Lulder JA, Hendriks T, Curfs JHAJ, Van-Der-linden CJ, Sauerwein RW, Differential induction of pro­ and anti­inflammatory cytokines in whole blood by bacteria: effects of antibiotic treatment. Antimicrob Agents Chemother 1997, 41:1439--1443
29	Arditi M, Kabat W, Yoger R, Antibiotic­induced bacterial killing stimulated tumor necrosis factor­α release in whole blood. J Infect Dis 1993, 167:240--244
30	Norimatsu M, Morrison DC, Correlation of antibiotic­induced endotoxin release and cytokine production in Escherichia coliinoculated mouse whole blood ex vivo. J Infect Dis 1998, 177:1302--1307
31	Trautmann M, Zick R, Rukavina T, Cross AS, Marre R, Antibiotic­induced release of endotoxin: in vitro comparison of meropenem and other antibiotics. J Antimicrob Chemother 1998, 41:163--169
32	Trautmann M, Heitemann M, Zick R, Moricke A, Seidelmann M, Berger D, Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic­induced morphological changes and endotoxin­liberating effects. Eur J Clin Microbiol Infect Dis 1998, 17:754--760
33	Trautmann M, Heineman N, Moriche A, Seidelmann M, Lorenz I, Berger D, ET AL. Endotoxin release due to ciprofloxacin measured by three different methods. J Chemother 1999, 11:248--254
34	Purswani M, Eckert S, Arora H, JIHANN­LIANG R, NOEL G J. The effect of three broad­spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for down­regulation of cytokine mRNA transcription by trovafloxacin. J Antimicrob Chemother 2000, 46:921--929
35	Stuertz K, Schmidt H, Eiffer TH, Schwartz P, Mader M, Nau R, Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to β­lactam antibiotics, rifamycins, trovafloxacin, and quinupristin­dalfopristin. Antimicrob Agents Chemother 1998, 42:277--281
36	Yokochi T, Narita K, Morikawa A, Takahashi K, Kato Y, Sugiyama T, ET AL. Morphological changes in Pseudomonas aeruginosa following antibiotic treatment of experimental infection in mice and its relation to susceptibility to phagocytosis and to release of endotoxin. Antimicrob Agents Chemother 2000, 44:205--206
37	Maury E, Barakett V, Blanchard H, Guitton C, Fitting C, Vassal T, ET AL. Circulating endotoxin during initial antibiotic treatment of severe Gram­negative bacteremic infections. J Infect Dis 1998, 178:270--272
38	Simpson AJH, Opal SM, Angus BJ, Prins JM, Palardy JE, Parejo NA, ET AL. Differential antibiotic­induced endotoxin release in severe melioidosis. J Infect Dis 2000, 181:1014--1019
39	GIAMARELLOS-­BOURBOULIS E J, PERDIOS J, LELEKIS M, EOCONOMOU E, TSOUROULAS P, GIAMARELLOU H. Impact of cefuroxime administration on endotoxin (LPS) and tumor necrosis factor­α (TNFα) blood levels in patients suffering from acute pyelonephritis: a preliminary report. Int J Antimicrob Agents 1999, 11:115--119
40	Annane D, Corticosteroids for septic shock. Crit Care Med 2001, 29(Suppl):S117--S120
41	Arndt P, Abraham E, Immunological therapy for sepsis. Intensive Care Med 2001, 27(Suppl 1):S104--S115
42	Dankesreiter S, Hoess A, SCHNEIDER­MARGENER J, WAGNER H, MIETHKE T. Synthetic endotoxin­binding peptides block endotoxin­triggered TNFα production by macrophages in vitro and in vivo and prevent endotoxin­mediated toxic shock. J Immunol 2000, 164:4804--4811
43	Reinhart K, Karzai W, Anti­tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001, 29(Suppl 1):S121--S125
44	Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, ET AL. Lenercept (p55 tumor necrosis factor receptor protein) in severe sepsis and early septic shock: a randomized, double­blind, placebo­controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001, 29:503--505
45	Yoshinari D, Takeyoshi I, Koibuchi Y, Matsumoto K, Kawashima Y, Koyama T, ET AL. Effects of a dual inhibitor of tumor necrosis factor­α and interleukin­1 on lipopolysaccharide­induced lung injury in rats: involvement of the p38 mitogen­activated protein kinase pathway. Crit Care Med 2001, 29:628--634
46	Remick DG, Call DR, Ebong SJ, Newcomb DE, Nybom P, Nemzek JA, ET AL. Combination immunotherapy with soluble tumor necrosis factor receptors bolus interleukin­1 receptor antagonist decreases sepsis mortality. Crit Care Med 2001, 29:473--481
47	Frishman JI, Edwards C, K-III, SONNENBERG M G, KOHNO T, COHEN A M, DINARELLO C A. Tumor necrosis factor­α­induced interleukin­8 in human blood cultures discriminates neutralization by the p55 and the p75 TNF soluble receptors. J Infect Dis 2000, 182:1722--1730
48	Hotchkiss RS, Karl IE, Cytokine blockade in sepsis. Are two better than one? Crit Care Med 2001, 29:671--672
49	WELTY­WOLF K E, CARAWAY M S, HUANG Y C T, SIMONSON S G, KANTROW S P, KISHIMOTO T K ET AL. Antibody to intercellular adhesion molecule 1 (CD54) decreases survival and not lung injury in baboons with sepsis. Am J Respir Crit Care Med 2001, 163:665--673
50	Turek JJ, Schoenlein IA, Watkins BA, Van-Alstine WG, Clark LK, Knox K, Dietary polyunsaturated fatty acids modulate responses of pigs to Mycoplasma hyopneumoniae infection. J Nutr 1996, 126:1541--1548
51	Watanabe S, Onozaki K, Yamamoto S, Okuyama H, Regulation by dietary essential fatty acid balance of tumor necrosis factor production in mouse macrophages. J Leukoc Biol 1993, 53:151--156